103 related articles for article (PubMed ID: 4048798)
1. Influencing immune perturbations by prolonged corticotherapy in the chronic active liver disease.
Banciu T; Arcan P; Stroe A
Med Interne; 1985; 23(3):177-83. PubMed ID: 4048798
[TBL] [Abstract][Full Text] [Related]
2. Variations in humoral and cellular immunologic changes in relation to the evolutive stage of chronic active liver disease.
Banciu T; Argan P; Suşan L; Ocică I; Perţa D
Med Interne; 1987; 25(1):25-30. PubMed ID: 3495858
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune complexes in chronic hepatitis as related to the presence of HBsAg.
Radu D; Dumitraşcu D; Părău N; Urcan S; Stanciu L; Tăpălagă D; Ban A; Dumitraşcu D; Rusu C
Med Interne; 1984; 22(1):61-5. PubMed ID: 6710050
[TBL] [Abstract][Full Text] [Related]
4. [The immune compartment in chronic active liver disease responsive and non-responsive to corticoid therapy].
Buligescu L; Mateescu-Cutcudache O; Mihai E
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(1):91-5. PubMed ID: 2884716
[No Abstract] [Full Text] [Related]
5. Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis.
Eggink HF; Houthoff HJ; Huitema S; Gips CH; Poppema S
Clin Exp Immunol; 1982 Oct; 50(1):17-24. PubMed ID: 6983407
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of clinical effectiveness of colchicine in the treatment of chronic active hepatitis with transformation to liver cirrhosis].
Simon K; Gładysz A; Zalewska M; Machaj A
Przegl Epidemiol; 1991; 45(4):331-4. PubMed ID: 1841412
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial.
Romeo F; Arcoria D; Palmisano L; Polosa P
Arzneimittelforschung; 1985; 35(8):1317-22. PubMed ID: 3907642
[TBL] [Abstract][Full Text] [Related]
8. Loss of suppressor T cell function and circulating immune complexes in chronic active liver diseases.
Hotta R; Kuriki J; Kakumu S
Clin Exp Immunol; 1981 Nov; 46(2):375-81. PubMed ID: 6461458
[TBL] [Abstract][Full Text] [Related]
9. Immunological studies in HBV-related chronic liver diseases.
Joshi N; Ayesha Q; Habibullah CM
Indian J Pathol Microbiol; 1990 Oct; 33(4):351-4. PubMed ID: 2132503
[TBL] [Abstract][Full Text] [Related]
10. The interference of an autoimmune mechanism in the pathogeny of chronic active liver diseases.
Banciu T; Arcan P; Văcariu V; Tudose N
Med Interne; 1989; 27(1):47-52. PubMed ID: 2749158
[TBL] [Abstract][Full Text] [Related]
11. [The effect of withdrawal on humoral and cellular immune changes in alcoholic hepatopathy].
Banciu T; Arcan P; Suşan L; Ocică I; Sorian E
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1989; 41(4):363-8. PubMed ID: 2573946
[TBL] [Abstract][Full Text] [Related]
12. [The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results].
Kokoreva LN; Zmyzgova AV; Shalygina NB
Ter Arkh; 1996; 68(2):10-4. PubMed ID: 8771646
[TBL] [Abstract][Full Text] [Related]
13. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the circulating immune complexes in acute and chronic liver diseases.
Schena FP; Pastore G; Pastore A; Angarano G; Meliconi L; Schiraldi O; Bonomo L
J Clin Lab Immunol; 1983 Apr; 10(4):179-83. PubMed ID: 6864764
[TBL] [Abstract][Full Text] [Related]
15. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.
Davis GL; Czaja AJ; Ludwig J
Gastroenterology; 1984 Dec; 87(6):1222-7. PubMed ID: 6489694
[TBL] [Abstract][Full Text] [Related]
16. Oral pulse prednisone therapy in the treatment of HBsAg negative chronic active hepatitis.
Chase WF; Winn RE; Mayes GR
Gastroenterology; 1982 Dec; 83(6):1292-6. PubMed ID: 7129032
[TBL] [Abstract][Full Text] [Related]
17. Circulating complement fixing immune complexes in chronic hepatitis. Use of anti-C3 enzyme immunoassay to define antibody class and nature of antigen.
Sagnelli E; Felaco FM; Triolo G; Vernace SJ; Filippini P; Piccinino F; Behrens U; Paronetto F
J Clin Lab Immunol; 1983 Sep; 12(1):11-5. PubMed ID: 6195340
[TBL] [Abstract][Full Text] [Related]
18. [Immunosuppressive therapy in patients with HBeAg-positive chronic active hepatitis B?].
Maier KP; Lepiorz H; Berthold H; Gerok W
Leber Magen Darm; 1982 Aug; 12(4):150-3. PubMed ID: 7132529
[TBL] [Abstract][Full Text] [Related]
19. Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B.
Eggink HF; Houthoff HJ; Huitema S; Wolters G; Poppema S; Gips CH
Clin Exp Immunol; 1984 Apr; 56(1):121-8. PubMed ID: 6713726
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of circulating immune complexes during acute exacerbation of chronic viral hepatitis.
Araki K; Nagashima H; Tsuji T
Clin Exp Immunol; 1982 Mar; 47(3):520-6. PubMed ID: 6282506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
